Agents such as erlotinib used for EGFR-mutant non-small cell lung cancer or imatinib for chronic myeloid leukemia, for instance, lead to rapid tumor responses. The gene discussed is EGFR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.